Research and development expenses for the quarter ended June 30, 2010 totaled $4.1 million, compared to $3.8 million for the second quarter of 2009. General and administrative expenses were $1.2 million for the second quarter of 2010, compared to $0.8 million for the second quarter of 2009. Marketing expenses were $0.4 million for the second quarter of 2010, compared to $0.2 million for the second quarter of 2009.

As of June 30, 2010, Alimera had cash, cash equivalents and investments of $60.2 million, compared to $4.9 million as of December 31, 2009.

Financial Outlook

Alimera anticipates that it will incur research and development expenses of approximately $11.6 million and $1.8 million during 2010 and 2011, respectively, to complete the clinical development and registration of Iluvien?® for DME. Upon approval of Iluvien?® by the FDA, Alimera will owe an additional milestone payment of $25.0 million to pSivida.

The Company anticipates significant increases in marketing and selling expenses as Alimera hires additional personnel and establishes sales and marketing capabilities in anticipation of the commercialization of Iluvien?®. Alimera intends to market and sell Iluvien?® to the approximately 1,600 retinal specialists practicing in the approximately 900 retina centers across the United States and Canada.

Alimera believes its current cash, cash equivalents and investments are sufficient to fund operations through the projected commercialization of Iluvien?® and the expected generation of revenue in 2011.

SOURCE Alimera Sciences, Inc.